Learn more about Amarin's first commercialized product
We operate or partner to make our medicines available in more than 15 countries. To report an adverse event or a product complaint, or to request information about our products, please visit our contact us page. Please note, not all products are available in every country listed on the adverse events page.
VASCEPA®/VAZKEPA®▼ (icosapent ethyl) is a prescription-only medicine
This means it can only be prescribed by a suitably qualified healthcare professional who can assess its suitability for individual patients.
▼ Vazkepa is subject to additional monitoring in the EU. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.
WHAT TO DO IF YOU EXPERIENCE SIDE EFFECTS WHILE TAKING AN AMARIN MEDICINE
If you are taking a prescribed Amarin medicine and experience any side effects, you should immediately report these to your doctor, to another healthcare professional (such as a nurse or caretaker), or via the national reporting system.
LEADING A NEW PARADIGM IN CARDIOVASCULAR HEALTH
The science behind the development of cardiovascular disease is complex. Our current treatment targets persistent cardiovascular risk reduction in patients at high- or very high risk - on statin therapy. We do this by focusing on science, research, passion and global knowledge to ensure we can stop heart disease from being a leading cause of death.
At Amarin, we’re committed to providing breakthrough treatments, scientific understanding and expertise.
A BOLD investment in cardiometabolic health
Keeping our investors informed about our progress in helping stop cardiovascular disease from being a leading cause of death is important to us. Click here for our investor presentations, events and financial results.